ECM Weekly (21 February 2021) - Tencent Lock-Up Expiry, SciClone Pharma, Joinn Lab, Bairong, Betta
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
558 Views
SciClone Pharmaceuticals IPO: Valuation Insights
SciClone has launched its IPO to raise net proceeds of $252m, at the mid-point of the price range. We recommend a pass as our concerns on the...
873 Views
SciClone (赛生药业) IPO: A Mediocre Deal
We think the cornerstone is mediocre and the deal is fairly valued. The recent reference deal of its close peer, Simcere, has done poorly. We will...
532 Views
JOINN Laboratories IPO: Attractive Valuation; Overseas Expansion Should Open Up Room for LT Growth
Joinn Laboratories, the pioneer of commercial GLP laboratories in China has filed for a secondary listing to list its shares on the Hong Kong Stock...
263 Views
SciClone Pharmaceutical IPO: Future Prospects for Zadaxin Troubling
SciClone Pharmaceuticals, a biopharmaceutical company with an integrated platform for product development and commercialisation has filed for an...
290 Views